title: Deferiprone attenuates inflammation and myocardial fibrosis in diabetic cardiomyopathy rats.
abstract: We attempted to investigate the therapeutic effects of deferiprone on DC rats and explore the underlying mechanism. Total 24 6-week-old male Wistar rats (weighing from 180 g to 220 g) were subjected to DC model construction and then randomly divided to three groups (8 rats per group): DC group, DC + 50 mg, and DC + 100 mg deferiprone treatment group. The 8 normal rats were considered as controls. After deferiprone treatment for 20 weeks, the blood samples were collected for the biochemical parameters test, including fasting glucose, HOMA-IR (homeostasis model assessment of the insulin resistance), serum iron, ferritin and transferrin saturation (TS). The oxidative stress was assessed by detecting the level of malondialdehyde (MDA) and superoxide dismutase (SOD). Histopathologic changes were determined by Masson's trichrome staining and electron microscopy imaging. The expression levels of NF-κB (nuclear factor kappa B), COX2 (cytochrome c oxidase), tenascin C, collagen IV were measured by RT-PCR and western blotting. The expression of nitrotyrosine and MCP-1 (monocyte chemotactic protein 1) were determined by immunohistochemistry. Deferiprone treatment reduced iron deposition and IR in DC rats except for blood glucose. After deferiprone treatment, MDA level was significantly decreased and SOD level was increased significantly. The level of NF-κB, cyclooxygenase-2, tenascin C, collagen IV MCP-1 and nitrotyrosine were significantly reduced. There was no significant difference in the effect of deferiprone at 50 and 100 mg doses. Deferiprone showed therapeutic effects on DC by regulating the pro-inflammatory and pro-fibrotic factors.
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China.
authors.forename: Chunbo
authors.initials: C
authors.lastname: Zou
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China. Electronic address: xiaogangliuu@163.com.
authors.forename: Xiaogang
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China.
authors.forename: Rujuan
authors.initials: R
authors.lastname: Xie
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China.
authors.forename: Yushi
authors.initials: Y
authors.lastname: Bao
authors.affiliation: Department of Nephrology, Heilongjiang Provincial Hospital, Harbin 150036, People's Republic of China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Jin
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China.
authors.forename: Xibei
authors.initials: X
authors.lastname: Jia
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Nephrology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China.
authors.forename: Ruichan
authors.initials: R
authors.lastname: Liu
mesh_terms: D000818:Animals; D000077543:Deferiprone; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004719:Endomyocardial Fibrosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D007155:Immunologic Factors / Q000276:immunology; D007502:Iron Chelating Agents / Q000008:administration & dosage; D008297:Male; D009205:Myocarditis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects / Q000276:immunology; D011728:Pyridones / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D007502:Iron Chelating Agents; D011728:Pyridones; D017382:Reactive Oxygen Species; D000077543:Deferiprone
keywords: Deferiprone; Diabetic cardiomyopathy; Fibrosis; Inflammatory